Gilead Sciences, Inc. (NASDAQ:GILD) was downgraded by research analysts at Maxim Group from a “buy” rating to a “hold” rating in a report released on Friday, The Fly reports.
Gilead Sciences (NASDAQ:GILD) opened at 97.00 on Friday. The company has a market cap of $132.58 billion and a price-to-earnings ratio of 8.14. Gilead Sciences has a 52-week low of $81.89 and a 52-week high of $123.37. The stock has a 50 day moving average of $95.09 and a 200-day moving average of $97.31.
Gilead Sciences (NASDAQ:GILD) last issued its earnings results on Thursday, April 28th. The biopharmaceutical company reported $3.03 earnings per share for the quarter, missing the Zacks’ consensus estimate of $3.13 by $0.10. The business earned $7.80 billion during the quarter, compared to analyst estimates of $8.08 billion. During the same period in the prior year, the firm posted $2.94 EPS. The business’s quarterly revenue was up 2.6% compared to the same quarter last year. On average, analysts forecast that Gilead Sciences will post $12.33 EPS for the current year.
Source: Web Breaking News